Two by Two Factorial Design using Metformin and Curcumin for Second Primary Head and Neck Cancer Prevention Trial
- PMID: 38918654
- DOI: 10.31557/APJCP.2024.25.6.1935
Two by Two Factorial Design using Metformin and Curcumin for Second Primary Head and Neck Cancer Prevention Trial
Abstract
Objective: The 2x2 factorial design is an effective method that allows for multiple comparisons, especially in the context of interactions between different interventions, without substantially increasing the required sample size. In view of the considerable preclinical evidence for Curcumin and Metformin in preventing the development and progression of head and neck squamous cell carcinoma (HNSCC), this study describes the protocol of the clinical trial towards applying the drug combination in prevention of second primary tumors.
Methods: We have applied the trial design to a large phase IIB/III double-blind, multi-centric, placebo-controlled, randomized clinical trial to determine the safety and efficacy of Metformin and Curcumin in the prevention of second primary tumours (SPT) of the aerodigestive tract following treatment of HNSCC (n=1,500) [Clinical Registry of India, CTRI/2018/03/012274]. Patients recruited in this trial will receive Metformin (with placebo), Curcumin (with placebo), Metformin, and Curcumin or placebo alone for a period of 36 months. The primary endpoint of this trial is the development of SPT, while the secondary endpoints are toxicities associated with the agents, incidence of recurrence, and identifying potential biomarkers. In this article, we discuss the 2x2 factorial design and how it applies to the head and neck cancer chemoprevention trial.
Conclusion: 2x2 factorial design is an effective trial design for chemoprevention clinical trials where the effectiveness of multiple interventions needs to be tested parallelly.
Keywords: Keywords: Head and Neck Squamous cell Carcinoma; Metformin; Second Primary Tumour; curcumin.
Similar articles
-
Curcumin and analogues against head and neck cancer: From drug delivery to molecular mechanisms.Phytomedicine. 2023 Oct;119:154986. doi: 10.1016/j.phymed.2023.154986. Epub 2023 Jul 21. Phytomedicine. 2023. PMID: 37506572 Review.
-
Buparlisib and paclitaxel in patients with platinum-pretreated recurrent or metastatic squamous cell carcinoma of the head and neck (BERIL-1): a randomised, double-blind, placebo-controlled phase 2 trial.Lancet Oncol. 2017 Mar;18(3):323-335. doi: 10.1016/S1470-2045(17)30064-5. Epub 2017 Jan 26. Lancet Oncol. 2017. PMID: 28131786 Clinical Trial.
-
Afatinib versus placebo as adjuvant therapy after chemoradiation in a double-blind, phase III study (LUX-Head & Neck 2) in patients with primary unresected, clinically intermediate-to-high-risk head and neck cancer: study protocol for a randomized controlled trial.Trials. 2014 Nov 29;15:469. doi: 10.1186/1745-6215-15-469. Trials. 2014. PMID: 25432788 Free PMC article. Clinical Trial.
-
The impact of smoking status, disease stage, and index tumor site on second primary tumor incidence and tumor recurrence in the head and neck retinoid chemoprevention trial.Cancer Epidemiol Biomarkers Prev. 2001 Aug;10(8):823-9. Cancer Epidemiol Biomarkers Prev. 2001. PMID: 11489748 Clinical Trial.
-
Retinoid chemoprevention of second primary tumors.Semin Hematol. 1994 Oct;31(4 Suppl 5):26-30. Semin Hematol. 1994. PMID: 7831582 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical